Cambridge, UK: 08 June 2021
One Nucleus, the non-for-profit Life Science membership group headquartered in Cambridge exists to support growing Life Science businesses throughout their life cycle as they translate great science into better patient outcomes. This includes bringing connections to expert advisers and business intelligence sources to enable members to create their corporate development plans from a position of knowledge. PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For nearly 30 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.
Dr Fintan Walton, CEO and Founder of PharmaVentures commented, “PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts makes us uniquely placed to support business in all aspects of deal making and strategic planning in the life sciences space. These include M&A, licensing and fundraising deals across the world. We are always keen to give back to the sector, supporting companies and investors alike in making informed decisions, and joining the One Nucleus Partner Programme provides a mechanism to share our insight to support the broad range of life science businesses that are One Nucleus members.”
Tony Jones, CEO of One Nucleus expands further “One Nucleus aims to be here to support our members through every aspect of their journey, from ideation to exit. Partnering with PharmaVentures in this way means we can bring that insight and support to our members as they plot their investment and partnering strategies.”